13611-97-7

Usage

Uses

Used in Hormonal Disorder Treatment:
(5alpha,17xi)-17-hydroxypregn-20-yn-3-one is used as a medication for treating hormonal disorders, as it helps regulate hormone levels and alleviate symptoms associated with these conditions.
Used in Pregnancy Support:
(5alpha,17xi)-17-hydroxypregn-20-yn-3-one is used as a supportive medication during pregnancy to prevent complications and ensure a healthy development of the fetus.
Used in Synthesis of Other Steroid Hormones:
(5alpha,17xi)-17-hydroxypregn-20-yn-3-one is used as an intermediate in the synthesis of other steroid hormones, such as cortisol and androgens, which have various physiological functions in the body.
Used in Endometriosis Treatment:
(5alpha,17xi)-17-hydroxypregn-20-yn-3-one is used as a potential treatment for endometriosis, a condition where the tissue that lines the uterus grows outside of it, causing pain and other complications.
Used in Cancer Treatment:
(5alpha,17xi)-17-hydroxypregn-20-yn-3-one is used in the study and potential treatment of certain types of cancer, as it may have an impact on the growth and progression of cancer cells.

Upstream product

• 13611-96-6 (3S,5S,8R,9S,10S,13S,14S,17R)-17-Ethynyl-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthrene-3,17-diol 
• 481-29-8 Epiandrosterone 

Downstream Products

• 129163-98-0 17-(2-Iodovinyl)dihydrotestosterone 
• 64584-52-7 (5S,8R,9S,10S,13S,14S,17R)-17-Ethynyl-17-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-one O-(4-nitro-phenyl)-oxime 
• 20112-30-5 17beta-Hydroxy-17alpha-ethyl-5alpha-androstan-3-one 
• 144177-30-0 Win 51708 

Relevant academic research and scientific papers

Selective manipulation of steroid hydroxyl groups with boronate esters: Efficient access to antigenic C-3 linked steroid-protein conjugates and steroid sulfate standards for drug detection

The temporary protection of 17α-alkyl-5α-androstane-3β, 16β,17β triols as boronate esters is an efficient method for their regioselective functionalisation. This has been applied to the synthesis of protein-steroid conjugates 7-10 suitable for the develop

A potential radioiodinated ligand for androgen receptor: 7α-methyl-17α-(2'-(E)-iodovinyl)-19-nortestosterone

The presence of androgen receptor (AR) in prostate cancer has been linked to the androgen-dependent nature of the tumor and has also been shown to have prognostic significance; it also appears to be a positive prognostic indicator in breast cancer. However, due to the relatively low AR concentrations in most tumors and the inherently low specific activity of tritium, the assay of AR based on available 3H-ligands is not sensitive enough to measure accurately the amount of receptor in small specimens. A 125I-ligand like those available for the estrogen and progesterone receptors would be helpful, but development of such a ligand for AR has not been very successful. Although several androgen analogues containing iodine, bromine, or selenium have been synthesized specifically as potential probes for AR, none have shown any significant affinity or specificity for the receptor. We therefore undertook the synthesis of new potential AR ligands which could be radioiodinated, and determined their affinities for AR (from rat uterus and MCF-7 human breast cancer cells) by using a competition assay. We have examined both 5α-dihydrotestosterone (5α-DHT) and 19-nortestosterone analogues and have identified two such compounds which showed high AR affinity: (17α,20E)-17β-hydroxy-21-iodo-5α-pregn-20-en-3-one (17α-((E)-iodovinyl)-5α-DHT, 9) and 17β-hydroxy-7α-methyl-(17α,20E)-21-iodo-19-norpregna-4,20-dien-3- one (7α-methyl-17α-((E)-iodovinyl)-19-nortestosterone, 11). In fact, the affinity of the latter for human AR was found to be superior to that of 5α-DHT itself. These iodovinyl analogues could be easily prepared in the radioiodinated form, and should prove to be extremely useful in assaying low levels of AR in small specimens.